Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd declared to have signed a series of cooperation agreements with Saladax Biomedical, Inc. from USA. With a total investment of approximately 22.5 million USD to subscribe Saladax’ series-D issuance of preferred shares, Fosun Pharma will become the single largest shareholder of Saladax after completion of the transaction. At the same time, Shanghai Fosun Long March Medical Science Co., Ltd (“Fosun Long March”), a wholly-owned subsidiary of Fosun Pharma, has signed a strategic cooperation agreement with Saladax to have the exclusive distribution and manufacturing rights in China authorized by Saladax.
Saladax owns the leading diagnosise technology and the cancer chemotherapy drug monitoring product portfolio. This cooperation will effectively enhance Fosun Pharma’s innovation ability in the field of medical diagnosis and hopefully launch an original biochemical detection platform in China and even in the global market, enabling diagnose of cancer chemotherapy drug concentration and help to better analyze the therapeutic efficacy of tumor chemotherapy drugs. This pipe-line is expected to bring considerable sales volume in China in the future. Both Saladax and Fosun Pharma have expressed confidence in the prospects for cooperation.

Link:
Fosun Long March: a wholly-owned subsidiary of Fosun Pharma. Founded in 1989, Fosun Long March is a medical diagnostic company under Fosun Pharma, specializes in researching and manufacturing biochemical reagents, immune-reagents, clinical testing and analytical instruments, laboratory reagents and type III clinical testing and analytical instruments.
Saladax: founded in 2004 in USA by former Roche executive team, Saladax is a private company specializes in tailored drug dose diagnostic tests. Its exclusive MyCare™ detection line improves the efficacy of existing drugs through optimizing dosage. The broadly flexible technical platform MyCare can be used in many therapeutic areas such as to optimize medicament, overcome the narrow therapeutic index and realize the best efficacy / toxicity balance. Its current technical platform and tumor chemotherapy drug monitoring product portfolio is world leading, which can basically monitor 50-60% commonly used cancer chemotherapy drugs, and up to 80-90% with subsequent two or three years of development. In addition, companion diagnostics technology service is also available for large pharmaceutical companies.